Identification of XXXX -specific antibodies in @entity1 with @entity0 vaccinated with gene-modified @entity5 cells.

@entity1 @entity0 @entity5 @entity7938 @entity876 @entity2355 @entity2841 @entity2241 @entity1722
Thirty HLA-A2 @entity1 with metastatic @entity0 received up to 14 vaccinations with MDA-MB-231- @entity7938 , an HLA-A2 allogeneic @entity0 cell line, which had been lipofected with the cDNA for the @entity7938 costimulatory molecule. @entity5 cells were administered with BCG or @entity2841 as an adjuvant. Sera obtained before and after vaccination were analyzed for antibodies to @entity5 cell lysate, @entity2355 , @entity1722 / @entity1722 and @entity876 . Since the cell line was grown in @entity2241 ( @entity2241 ), sera were also analyzed for antibodies to @entity2241 . Eighteen of 24 @entity1 for whom sera were available exhibited anti- @entity2241 activity at baseline. Eleven of these 18 @entity1 and all six @entity1 without baseline anti- @entity2241 activity showed an increased titer after vaccination. The anti- @entity2241 activity required that serum samples be absorbed in excess @entity2241 to detect specific antibodies to @entity5 cell lysate. A two-fold increase in the titer of IgG specific to @entity5 cell lysate was observed in 6 @entity1 . Eight of 24 @entity1 made an antibody response to @entity1722 , four of 24 to @entity2355 and one of 24 to @entity876 . Although antibody production to a variety of @entity5 cell-associated antigens was detected our results suggest that a whole cell vaccine comprising a @entity7938 -transfected allogeneic @entity0 cell line with adjuvant BCG or @entity2841 was not a reliable method to induce significant antibody responses in @entity1 with @entity0 .
